

Consensus Statement Genitourinary Malignancies

Daniel P. Petrylak, MD

Director, Genitourinary Oncology

Co Director, Signal Transduction
Program

Yale Comprehensive Cancer Center

Bladder Cancer

- ADCs such as Enfortumab Vedotin and IMU132 will be approved by the FDA within the next 18 months for metastatic urothelial cancer
- Immune checkpoint therapy will be moved up front for the treatment of metastatic urothelial cancer combined with chemotherapy

Bladder Cancer

- The next 5 years
 - Immune checkpoint therapy will be approved for BCG failures
 - Enfortumab Vedotin and IMU132 will form the basis for combination therapy with immune checkpoint inhibitors.